BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 15909810)

  • 21. Treatment for anthracycline-pretreated metastatic breast cancer.
    O'Shaughnessy J; Twelves C; Aapro M
    Oncologist; 2002; 7 Suppl 6():4-12. PubMed ID: 12454314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer.
    Saeki T; Takashima S
    Breast Cancer; 2004; 11(2):116-20. PubMed ID: 15550855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Combination of docetaxel and capecitabine for the treatment of anthracycline-resistant advanced breast carcinoma].
    Zhang JD; Shao ZY
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):787-9. PubMed ID: 19173816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine plus cisplatin for the treatment of metastatic breast cancer.
    Heinemann V
    Clin Breast Cancer; 2002 May; 3 Suppl 1():24-9. PubMed ID: 12057042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.
    Jassem J; Fein L; Karwal M; Campone M; Peck R; Poulart V; Vahdat L
    Breast; 2012 Feb; 21(1):89-94. PubMed ID: 21937232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
    Michalaki V; Gennatas S; Gennatas K
    Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer.
    Somali I; Alacacioglu A; Tarhan MO; Meydan N; Erten C; Usalp S; Yilmaz U
    Chemotherapy; 2009; 55(3):155-60. PubMed ID: 19390188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
    Michalaki V; Fotiou S; Gennatas S; Gennatas C
    Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).
    Ciruelos EM; Cortés J; Cortés-Funes H; Mayordomo JI; Bermejo B; Ojeda B; García E; Rodríguez CA; Muñoz M; Gómez P; Manso L; Andrés R; Lluch A; Saura C; Mendiola C; Baselga J
    Ann Oncol; 2010 Jul; 21(7):1442-1447. PubMed ID: 19940004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
    Reni M; Cereda S; Rognone A; Belli C; Ghidini M; Longoni S; Fugazza C; Rezzonico S; Passoni P; Slim N; Balzano G; Nicoletti R; Cappio S; Doglioni C; Villa E
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):115-23. PubMed ID: 21626049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer].
    Yu J; DI Lj; Song Gh; Che L; Jiang Hf; Zhu Yl; Liang X; Jia J; Zhang J; Yang Hb; Wang Xl; Zhou Xn; Ren J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):151-6. PubMed ID: 21321641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer].
    Li SF; Wang X; Wang C; He LH; Shi YH; Hao CF; Dong GL; Tong ZS
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):944-6. PubMed ID: 19174000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    O'Shaughnessy J; Miles D; Vukelja S; Moiseyenko V; Ayoub JP; Cervantes G; Fumoleau P; Jones S; Lui WY; Mauriac L; Twelves C; Van Hazel G; Verma S; Leonard R
    J Clin Oncol; 2002 Jun; 20(12):2812-23. PubMed ID: 12065558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines.
    Campone M; Dobrovolskaya N; Tjulandin S; Chen SC; Fourie S; Mefti F; Konstantinova M; Lefresne F; Meheust N; Jassem J
    Breast J; 2013; 19(3):240-9. PubMed ID: 23528159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines.
    Vici P; Giotta F; DI Lauro L; Brandi M; Gebbia V; Foggi P; Lorusso V; Vitucci C; Sergi D; Fattoruso SI; Giannarelli D; Viola G; Corsetti S; Colucci G; Lopez M
    Anticancer Res; 2009 May; 29(5):1841-5. PubMed ID: 19443414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer.
    Fan Y; Xu BH; Yuan P; Ma F; Wang JY; Ding XY; Zhang P; Li Q; Cai RG
    Ann Oncol; 2013 May; 24(5):1219-25. PubMed ID: 23223332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
    Soares HP; Bayraktar S; Blaya M; Lopes G; Merchan J; Macintyre J; Mayo C; Green MR; Silva O; Levi J; Walker G; Rocha-Lima CM
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):839-45. PubMed ID: 24562589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Sparano JA; Vrdoljak E; Rixe O; Xu B; Manikhas A; Medina C; Da Costa SC; Ro J; Rubio G; Rondinon M; Perez Manga G; Peck R; Poulart V; Conte P
    J Clin Oncol; 2010 Jul; 28(20):3256-63. PubMed ID: 20530276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.
    Perez EA; Hillman DW; Dentchev T; Le-Lindqwister NA; Geeraerts LH; Fitch TR; Liu H; Graham DL; Kahanic SP; Gross HM; Patel TA; Palmieri FM; Dueck AC
    Ann Oncol; 2010 Feb; 21(2):269-274. PubMed ID: 19901014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study.
    Brandi M; Vici P; Lopez M; Valerio MR; Giotta F; Gebbia N; Schittulli F; Colucci G;
    Semin Oncol; 2004 Apr; 31(2 Suppl 5):13-9. PubMed ID: 15199527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.